Data as of Dec 26
| -0.03 / -0.44%|
The 3 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 9.80, with a high estimate of 10.00 and a low estimate of 8.58. The median estimate represents a +43.65% increase from the last price of 6.82.
The current consensus among 3 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.